Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1996 1
1999 1
2000 1
2001 1
2003 2
2005 2
2006 1
2008 4
2009 1
2011 1
2012 2
2013 8
2014 1
2015 1
2016 1
2017 1
2018 3
2019 1
2020 1
2022 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial.
Esteve JL, Acosta R, Pérez Y, Rodriguez B, Seigler I, Sanchez C, Tomasi G. Esteve JL, et al. Int J Womens Health. 2013 Jun 25;5:361-9. doi: 10.2147/IJWH.S42770. Print 2013. Int J Womens Health. 2013. PMID: 23843709 Free PMC article.
TREATMENT: One daily capsule of 5 mg mifepristone or a mifepristone placebo over 3 months. VARIABLES IN EVALUATING SAFETY: Changes in fibroid and uterine volumes, changes in symptom prevalence and intensity, and changes in quality of life. ...Amenorrhea was 93.1% an …
TREATMENT: One daily capsule of 5 mg mifepristone or a mifepristone placebo over 3 months. VARIABLES IN EVALUATING SAFETY: Cha …
Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman.
Seth S, Goel N, Singh E, Mathur AS, Gupta G. Seth S, et al. J Midlife Health. 2013 Jan;4(1):22-6. doi: 10.4103/0976-7800.109630. J Midlife Health. 2013. PMID: 23833529 Free PMC article.
OBJECTIVES: To evaluate the effect of Mifepristone (25 mg) on symptomatic myoma in perimenopausal women. STUDY DESIGN: Open label clinical trial. ...CONCLUSION: Three months treatment of 25 mg Mifepristone effectively controls bleeding, reduces the uterine an …
OBJECTIVES: To evaluate the effect of Mifepristone (25 mg) on symptomatic myoma in perimenopausal women. STUDY DESIGN: Open la …
Selective progesterone receptor modulators: current applications and perspectives.
Chabbert-Buffet N, Kolanska K, Daraï E, Bouchard P. Chabbert-Buffet N, et al. Climacteric. 2018 Aug;21(4):375-379. doi: 10.1080/13697137.2017.1386650. Epub 2018 Jan 17. Climacteric. 2018. PMID: 29338440 Review.
Emergency contraception with extended activity was the second major development 30 years later, with mifepristone in some countries and ulipristal acetate world-wide. More recently, ulipristal acetate was released for the treatment of myoma-related uterine bleeding. …
Emergency contraception with extended activity was the second major development 30 years later, with mifepristone in some countries a …
Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial.
Esteve JL, Acosta R, Pérez Y, Campos R, Hernández AV, Texidó CS. Esteve JL, et al. Eur J Obstet Gynecol Reprod Biol. 2012 Apr;161(2):202-8. doi: 10.1016/j.ejogrb.2011.12.018. Epub 2012 Jan 23. Eur J Obstet Gynecol Reprod Biol. 2012. PMID: 22269473 Clinical Trial.
OBJECTIVES: To evaluate the efficacy and safety of 5 and 10mg doses of mifepristone for 6 months for the treatment of uterine fibroids and to check those results at 1 year post-treatment. ...One hundred and seventy-six women with symptomatic uterine fibroids received one d …
OBJECTIVES: To evaluate the efficacy and safety of 5 and 10mg doses of mifepristone for 6 months for the treatment of uterine fibroid …
Mifepristone Therapy in Symptomatic Leiomyomata Using a Variable Dose Pattern with a Favourable Outcome.
Jain D. Jain D. J Midlife Health. 2018 Apr-Jun;9(2):65-71. doi: 10.4103/jmh.JMH_100_17. J Midlife Health. 2018. PMID: 29962804 Free PMC article.
Every 3 months, the size of myomas, bleeding pattern, location of myomas, endometrial thickness, haemoglobin, and any side effects were all recorded. RESULTS: There was considerable amelioration in the symptoms in both premenopausal as well as perimenopausal women, …
Every 3 months, the size of myomas, bleeding pattern, location of myomas, endometrial thickness, haemoglobin, and any side eff …
Treatment of Uterine Myoma with 2.5 or 5 mg Mifepristone Daily during 3 Months with 9 Months Posttreatment Followup: Randomized Clinical Trial.
Carbonell JL, Acosta R, Pérez Y, Garcés R, Sánchez C, Tomasi G. Carbonell JL, et al. ISRN Obstet Gynecol. 2013 Jul 29;2013:649030. doi: 10.1155/2013/649030. eCollection 2013. ISRN Obstet Gynecol. 2013. PMID: 23984082 Free PMC article.
To evaluate the efficacy, safety, and quality of life by using 2.5 and mifepristone 5 mg daily doses to treat uterine fibroids over 3 months with a 9-month followup period. ...There were no significant differences in mifepristone side effects between the groups. Bot …
To evaluate the efficacy, safety, and quality of life by using 2.5 and mifepristone 5 mg daily doses to treat uterine fibroids over 3 …
Progesterone receptor antagonists.
Spitz IM. Spitz IM. Curr Opin Investig Drugs. 2006 Oct;7(10):882-90. Curr Opin Investig Drugs. 2006. PMID: 17086932 Review.
Since the discovery of the progesterone receptor antagonist mifepristone, numerous additional compounds, which display a spectrum of biological actions ranging from full antagonist to those with mixed agonist/antagonist activity, have been synthesized. ...Thus far, the maj …
Since the discovery of the progesterone receptor antagonist mifepristone, numerous additional compounds, which display a spectrum of …
Progestins and uterine leiomyoma.
Schweppe KW. Schweppe KW. Gynecol Endocrinol. 1999 Jun;13 Suppl 4:21-4. doi: 10.1080/gye.13.s4.21.24. Gynecol Endocrinol. 1999. PMID: 12227898 Free article. Review.
Myomas are the most frequent benign gynecological tumors and are responsible for several symptoms and complaints. ...Besides the importance of estrogens for development and growth of the myoma, progesterone seems to play an important role in the modulation of mitoti …
Myomas are the most frequent benign gynecological tumors and are responsible for several symptoms and complaints. ...Besides the impo …
Effects of antiprogestins on the uterus.
Ouzounian S, Bouchard P, Chabbert-Buffet N. Ouzounian S, et al. Womens Health (Lond). 2008 May;4(3):269-80. doi: 10.2217/17455057.4.3.269. Womens Health (Lond). 2008. PMID: 19072476 Free article. Review.
The main indications that will be developed in the future include dysfunctional bleeding and preoperative treatment of uterine myomas. Other future indications may include estrogen-free contraception, treatment of endometriosis and prevention and treatment of breast cancer …
The main indications that will be developed in the future include dysfunctional bleeding and preoperative treatment of uterine myomas …
38 results